ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C14H22N2O3
CAS番号:
分子量:
266.34
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
SMILES string
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
InChI key
METKIMKYRPQLGS-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
atenolol
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... ADRB1(153)
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Application
Atenolol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Atenolol Tablets
- Atenolol Injection
- Atenolol Compounded Oral Suspension
- Atenolol and Chlorthalidone Tablets
- Atenolol Compounded Oral Suspension, Veterinary
- Levobunolol Hydrochloride
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
1044403-200MG:
jan
Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity.
Sonia A Tabacova et al.
Reproductive toxicology (Elmsford, N.Y.), 16(1), 1-7 (2002-04-06)
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
M McGuiness et al.
Journal of the American Academy of Dermatology, 37(2 Pt 2), 298-299 (1997-08-01)
Atenolol is a beta-blocker commonly used for treating hypertension. It can induce various kinds of adverse side effects, including psoriasiform skin eruptions, skin necrosis, vasculitis, and (rarely) drug-induced connective tissue disease. We encountered a patient receiving atenolol for his hypertension
A N Wadworth et al.
Drugs, 42(3), 468-510 (1991-09-01)
Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours. The scope of therapeutic use of the drug has been expanded and become better defined since it was first reviewed in the Journal
Laura M Kuyper et al.
The Canadian journal of cardiology, 30(5 Suppl), S47-S53 (2014-04-23)
Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）